CD8A and neoplasm: In conjunction with recent studies (70, 74), our findings indicate that BET-i could be employed in combination with checkpoint blockade, CAR T cells, or bispecific antibodies (75, 76) to promote tumor clearance by enriching the TME with progenitor T cells expressing fewer exhaustion markers and sensitizing leukemic cells to CD8+ T cell–mediated killing.